iPSC Technology Patents: Who Leads, Where the Gaps Are 2026
- Filings peaked in 2018 at 48 and have since flattened, with 2022 sitting at 21 — the field is not accelerating, it is consolidating around established reprogramming methods.
- The top 5 assignees hold 27.8% of all 598 records, and the top 10 hold 45.0% — concentration is real but a long tail still files single or few applications each year.
- Core reprogramming patents from 2008-2010 remain the most cited works in the corpus, meaning the foundational claim space around factor-based reprogramming was staked out early and has not been displaced.
Filing growth compares 2021 (21 records) with 2024 (30) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 598 records in scope (CR5), not by the ranked leaders only.
What the iPSC patent record shows
Induced pluripotent stem cell technology sits at the intersection of cell reprogramming methods, genomic integrity controls, and downstream differentiation protocols aimed at clinical-grade output. The 598 records in scope span filings from 2015 through the current data cut-off, concentrated under C12N genetic engineering classes and layered with A61K medicinal preparation claims once reprogrammed cells move toward therapeutic use. Reprogramming efficiency and GMP-grade line language in the search scope points to a field that has moved past proof-of-concept and into manufacturing and regulatory-fit claims.
Filing activity rose through the late 2010s, peaked in 2018, and has trended flat to declining since — a pattern more consistent with claim consolidation around known reprogramming factors than with an expanding frontier. Publication lags filing by roughly 18 months, so the most recent years understate true filing activity; treat the 2025-2026 figures as provisional.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 598-record dataset: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
A peak in 2018, then a plateau
Filings ran from 23 in 2017 to a peak of 48 in 2018, settled to 21 at the 2022 midpoint, and stand at 3 in the still-incomplete most recent year. That trajectory reads as a field that staked its core claims early rather than one still in a land-grab phase.
Concentrated in genetic engineering and medicinal preparations
C12N covers all but one of the 598 records, confirming that nearly every filing touches genetic engineering or cell-line composition. A61K appears in 31.9% of records, marking the share that extends into formulated medicinal preparations, while C07K (14.5%) and A61P (11.0%) show smaller but material overlap into peptide chemistry and therapeutic-activity claims. Bioreactor and manufacturing-apparatus claims under C12M sit at just 2.3%, the smallest slice measured.
Shares are the percentage of the 598 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Induced Pluripotent Stem Cell Technology with Eureka
This page is one run against one query. Ask Eureka your own question about induced pluripotent stem cell technology and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited foundational filings
A method of generating an induced pluripotent stem cell, an induced pluripotent stem cell and methods of using the induced pluripotent stem cell
The method expresses exogenous nucleic acids encoding OCT3/4, SOX2, KLF4, LIN28 and L-MYC together with a p53-shRNA in a stem cell taken from the amniotic membrane of the umbilical cord, reprogramming it into an induced pluripotent stem cell. The filing also covers the resulting iPSC population and a pharmaceutical composition built from it.Filed by Cellresearch Corporation Pte Ltd, published 2023-09-14.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2008118820A2 | Somatic cell reprogramming | 586 |
| 2 | WO2010033906A2 | Efficient induction of pluripotent stem cells using small molecule compounds | 369 |
| 3 | US20090068742A1 | Nuclear Reprogramming Factor | 363 |
| 4 | WO2009102983A2 | Efficient induction of pluripotent stem cells using small molecule compounds | 255 |
| 5 | WO2010115050A2 | Embryonic stem cell specific micrornas promote induced pluripotency | 227 |
| 6 | US20080233610A1 | Somatic cell reprogramming | 223 |
| 7 | WO2010111422A2 | Induced pluripotent stem cell generation using two factors and p53 inactivation | 221 |
| 8 | US8129187B2 | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 | 215 |
| 9 | US20120207744A1 | Reprogramming compositions and methods of using the same | 198 |
| 10 | US8048999B2 | Nuclear reprogramming factor | 190 |
Citation counts inside a searched corpus favour older filings; read these as markers of influence on later work, not as a measure of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three patterns worth acting on before drafting new claims in this space.
The leader board is top-heavy but not closed
The leading assignee holds 43 records and the field drops to 24 at fifth place and 18 at tenth — a real gap at the top, but the top 10 still account for only 45.0% of all 598 records, leaving more than half the corpus to a long tail of single- and few-filing entrants.
Filing activity has cooled from its 2018 peak
Several of the most active historical filers show zero filings in the latest tracked year, including one assignee down -100% year over year. That does not necessarily mean retreat from the field — it is as consistent with maturity of a core portfolio as with reduced R&D investment, and the newest year is always undercounted due to publication lag.
Foundational reprogramming claims from 2008-2010 still anchor the field
The most-cited records in the corpus are all factor-based and small-molecule reprogramming methods published between 2008 and 2010. Their continued citation weight indicates that later filings build on, rather than replace, these core mechanisms.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to induced pluripotent stem cell technology, with the prior art for and against each one.
Who holds the claims, and where the gaps sit
Academic research institutes and a handful of specialised therapeutics companies dominate the ranked leaders, but co-filing activity is sparse — only 10 co-assignee pairs appear across the whole dataset, suggesting most organisations file independently rather than through joint ventures.
University and institute filers hold the earliest, most-cited ground
Research institutions account for several of the most active filers and sit behind the highest-cited records in the corpus, reflecting their role in establishing the original reprogramming methods that later commercial filings build on.
A cluster of therapeutics-focused filers sits just below the leaders
Companies working on specific reprogramming-to-therapy pipelines occupy the mid-tier of the ranking, filing steadily rather than in bursts, and their claims increasingly reach into A61K medicinal-preparation territory rather than staying in pure reprogramming-method claims.
Most of the field files once or twice, not repeatedly
More than half of all records sit outside the top 10 assignees, pointing to a field where new entrants can still stake claims in specific differentiation protocols or quality-control methods without displacing an entrenched incumbent.
| Assignee | Recent year | YoY |
|---|---|---|
| Kyoto University | 0 | — |
| The Scripps Research Institute | 0 | — |
| Genesis Tech Ltd | 0 | — |
| Wisconsin Alumni Research Foundation | 0 | — |
| Agency for Science, Technology and Research (A*STAR) | 0 | -100% |
| MOGRIFY LTD | 0 | — |
| Tenaya Therapeutics, Inc. | 0 | — |
| Asgard Therapeutics AB | 0 | -100% |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio positioning, or spotting where to file next.
Map claims against the highest-cited prior art
Before drafting new reprogramming-method claims, check them against the 2008-2010 foundational filings that still anchor citation counts across the corpus.
Explore prior art in EurekaTrack the assignees showing zero recent-year filings
Several previously active filers show no activity in the latest tracked year — worth confirming whether that reflects portfolio consolidation, expiry strategy, or a shift to trade secret protection.
Run assignee monitoring in EurekaProbe the under-claimed branches directly
Bioreactor apparatus and genomic-integrity screening carry the thinnest filing density in this dataset relative to core reprogramming claims, which is where new filings face the least crowded prior art.
Search white space in EurekaCommon questions about iPSC patents
The ranked leader in this dataset holds 43 of the 598 records in scope, with the field dropping to 24 records at fifth place and 18 at tenth. The leaders include a mix of academic research institutes and specialised therapeutics companies, and the ranking covers 100 assignees total rather than a small handful. Concentration is real at the very top but not overwhelming: the top 10 combined account for 45.0% of all records, leaving more than half the field to smaller filers.
No, filing activity peaked in 2018 at 48 records and has trended flat to declining since, with the 2022 midpoint at 21 and only 3 recorded in the most recent, still-incomplete year. This does not necessarily mean the field is shrinking — publication typically lags filing by about 18 months, so recent years are always undercounted. But the multi-year trend from the 2018 peak downward is a genuine pattern, not an artefact of lag alone.
This filing, from Cellresearch Corporation Pte Ltd and published 2023-09-14, claims a method of reprogramming amniotic membrane-derived umbilical cord stem cells into induced pluripotent stem cells using OCT3/4, SOX2, KLF4, LIN28 and L-MYC together with a p53-shRNA, plus the resulting cell population and a pharmaceutical composition built from it. It is a specific combination of reprogramming factors and starting cell source, not a claim over iPSC generation broadly. Anyone reprogramming a different starting tissue or using a different factor combination sits outside this particular claim scope, though should still check adjacent filings from the same family.
C12N, covering microorganisms and genetic engineering, appears in nearly all 598 records (99.8%), confirming it as the anchor class for this technology. A61K, medicinal preparations, follows at 31.9% of records, marking the point where reprogrammed cells are formulated toward therapeutic use. Smaller but material shares sit in C07K (peptides and proteins, 14.5%) and A61P (therapeutic activity, 11.0%), while manufacturing-apparatus claims under C12M remain the thinnest slice at 2.3%.
The thinnest filing density relative to the core reprogramming and medicinal-preparation classes sits in bioreactor and enzyme-apparatus claims (C12M, 2.3% of records), sterilisation methods for GMP-grade lines (A61L, 3.5%), and enzyme/DNA-based quality testing (C12Q, 3.8%). These are process and quality-control branches rather than the core reprogramming mechanism itself, and they carry noticeably less filing density than the C12N and A61K classes that dominate the corpus. That gap is where a new filer is least likely to run into crowded prior art.
Research Induced Pluripotent Stem Cell Technology in depth with Eureka
Go past this page: query the whole induced pluripotent stem cell technology corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.